Medical record review of transition to lanreotide following octreotide for neuroendocrine tumors

BACKGROUND: Octreotide has been used for decades in the United States (US) and Europe to treat patients with advanced neuroendocrine tumors (NETs). Lanreotide was approved in 2014 to improve progression-free survival (PFS) in patients with unresectable, well- or moderately-differentiated, locally ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Gastrointest Oncol
Main Authors: Saif, Muhammad Wasif, Parikh, Rohan, Ray, David, Kaye, James A., Kurosky, Samantha K., Thomas, Katharine, Ramirez, Robert A., Halfdanarson, Thorvardur R., Beveridge, Thomas J. R., Mirakhur, Beloo, Nagar, Saurabh P., Soares, Heloisa P.
Formato: Artigo
Idioma:Inglês
Publicado em: AME Publishing Company 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6657323/
https://ncbi.nlm.nih.gov/pubmed/31392048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2019.03.11
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados